| Vol. 15.32 – 24 August, 2023 |
| |
|
|
| Functional experiments indicated that 3,4-dihydroxyphenylglycol could be a key molecule mediating the therapeutic effect of TNF-α-preconditioned human umbilical cord MSCs. [Cellular And Molecular Life Sciences] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators tested the hypothesis that Zika virus functionally disrupted placental miRNAs, enabling viral persistence and fetal pathogenesis. [American Journal Of Obstetrics & Gynecology Mfm] |
|
|
|
| Commercially available human umbilical cord-MSCs were transplanted into eight-week-old MRL/lpr mice by tail vein injection. [Stem Cell Research & Therapy] |
|
|
|
| Scientists evaluated the biophysical properties of seven different carrageenan molecules at five different concentrations and their effect on human umbilical cord-derived MSC morphology, viability, metabolic activity, proliferation, extracellular matrix deposition and surface marker expression. [International Journal Of Biological Macromolecules] |
|
|
|
| In vitro studies were performed using HTR-8/SVneo cells that were cultured and treated with high glucose, sh-MUC1 and FH535, an inhibitor of Wnt/β-catenin signaling. [Biological Research] |
|
|
|
| Researchers explored the therapeutic potential of human placental MSCs in primary sclerosing cholangitis through the Takeda G protein-coupled receptor 5 (TGR5) receptor pathway. [Research] |
| |
|
|
|
| Two authors searcheed various registries for studies investigating the safety, feasibility, and efficacy of allogeneic cell therapy in neonates. The authors independently selected the articles, extracted data, and assessed the risk of bias. [Stem Cells Translational Medicine] |
|
|
|
|
| AlloNK is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved natural killer cell therapy candidate designed to enhance antibody-dependent cellular cytotoxicity. [Artiva Biotherapeutics Inc.] |
|
|
|
|
| October 11 – 14, 2023 Ottawa, Ontario, Canada |
|
|
|
|
|
| Amgen – Burnaby, British Columbia, Canada |
|
|
|
| RareCyte – Seattle, Washington, United States |
|
|
|
| Creative Biolabs – New York, New York, United States |
|
|
|
| US FDA – Silver Spring, Maryland, United States |
|
|
|
| IRB Barcelona – Barcelona, Spain |
|
|
|
|